回复：己烯雌酚、醋酸环丙孕酮、醋酸甲羟孕酮及磷酸雌莫司汀用于治疗晚期前列腺癌的心血管副作用：欧洲癌症研究与治疗组织试验30761和30762的结果 - Suppr | 超能文献

Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.

作者信息

deVoogt H J, Pavone-Macaluso M, Sylvester R, Schröder F H

出版信息

J Urol. 1988 Dec;140(6):1557. doi: 10.1016/s0022-5347(17)42118-5.

DOI:10.1016/s0022-5347(17)42118-5

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.回复：己烯雌酚、醋酸环丙孕酮、醋酸甲羟孕酮及磷酸雌莫司汀用于治疗晚期前列腺癌的心血管副作用：欧洲癌症研究与治疗组织试验30761和30762的结果

J Urol. 1988 Dec;140(6):1557. doi: 10.1016/s0022-5347(17)42118-5.

2

Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.己烯雌酚、醋酸环丙孕酮、醋酸甲羟孕酮和磷酸雌莫司汀用于治疗晚期前列腺癌的心血管副作用：欧洲癌症研究与治疗组织30761和30762试验的结果

J Urol. 1986 Feb;135(2):303-7. doi: 10.1016/s0022-5347(17)45620-5.

3

Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.

J Urol. 1986 Sep;136(3):624-31. doi: 10.1016/s0022-5347(17)44996-2.

4

EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.

Prog Clin Biol Res. 1989;303:111-6.

5

Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.醋酸环丙孕酮对比醋酸甲羟孕酮对比己烯雌酚治疗前列腺癌：欧洲癌症研究与治疗组织30761研究结果

Prog Clin Biol Res. 1987;243A:379-82.

6

Is there a best endocrine management of prostatic carcinoma?

Prog Clin Biol Res. 1988;269:147-58.

7

[Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].

Arch Esp Urol. 1982 Sep-Oct;35(5):304-11.

8

Hormonal therapy of advanced prostatic cancer.晚期前列腺癌的激素治疗

J Urol. 1986 Sep;136(3):653-4. doi: 10.1016/s0022-5347(17)45005-1.

9

Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.前列腺癌激素治疗的III期试验经验。I：欧洲癌症研究与治疗组织（EORTC）试验30761和30762的结果。

Prog Clin Biol Res. 1988;260:111-7.

10

Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.前列腺癌的治疗：欧洲癌症研究与治疗组织（EORTC）的经验——前列腺癌试验的初步结果

Prostate. 1984;5(2):193-8. doi: 10.1002/pros.2990050208.

引用本文的文献

1

The evolution of hormonal therapy for prostatic carcinoma.前列腺癌激素治疗的演变

Rev Urol. 2001;3 Suppl 3(Suppl 3):S1-9.

2

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.磷酸雌莫司汀钠。对其药效学、药代动力学特性及在前列腺癌治疗中的疗效的综述。

Drugs Aging. 1995 Jul;7(1):49-74. doi: 10.2165/00002512-199507010-00006.